NEW YORK–(BUSINESS WIRE)– Praesidian Capital, a leading private investment firm, announced today that it acquired an integrated clinical and laboratory services company in the high-growth field of genetic medicine. The company is a leader in the prenatal and preconception field, and it also provides hereditary cancer risk assessments. This is Praesidian’s first acquisition as an independent sponsor and will serve as a strong platform as Praesidian looks to expand the business across the country.
“The company’s unique and scalable business model is ideally suited for the high-growth genetic testing industry,” stated Jason Drattell, Praesidian Founder. “This acquisition provides an exciting foundation for Praesidian’s independent sponsor platform.”
Glenn Harrison, Praesidian Capital Partner said: “Genetic testing is now an integral part of patient care. We have some of the best clinicians in the industry and are eager to expand the company’s service offerings and footprint while continuing to provide industry leading care.”
“We are very excited about closing our first deal as an independent sponsor,” noted Tom Duffy, Managing Director. “As we build our equity portfolio, we will be evaluating add-on acquisitions as well as subsequent platform deals.”
About Praesidian Capital
Praesidian Capital is an innovative private investment firm focused on providing senior and subordinated debt along with growth capital to private lower middle market businesses in the United States, United Kingdom, Germany, and selectively in Northern Europe. Praesidian also recently launched a private equity strategy focused on control positions in lower middle market businesses. Based in New York with an office in London, Praesidian manages nearly $1 billion in committed capital. For more information, visit www.praesidian.com.
To discuss prospective investment opportunities please contact:
Glenn Harrison, Partner – email@example.com (212) 520-2612
Tom Duffy, Managing Director – firstname.lastname@example.org (212) 520-2617
Bill Johnston, Sr. Associate – email@example.com (212) 520-2632
The Abernathy MacGregor Group
Source: Praesidian Capital